title: No increase in breast cancer recurrence with concurrent use of tamoxifen and some CYP2D6-inhibiting medications.
abstract: Tamoxifen reduces recurrence risk among women treated for estrogen receptor-positive breast cancer. Its effectiveness partly depends on metabolic activation via cytochrome P450 2D6 (CYP2D6). Some medications compromise CYP2D6 activity and may lower plasma concentrations of active tamoxifen metabolites. We studied the association between concurrent use of tamoxifen and CYP2D6-inhibiting medications and breast cancer recurrence among Danish women diagnosed with early-stage, estrogen receptor-positive breast cancer. Using the Danish Breast Cancer Cooperative Group Registry, we identified 366 cases with local or distant breast cancer recurrence and 366 matched breast cancer controls. We ascertained concurrent prescription of CYP2D6-inhibiting medications during tamoxifen treatment by linking to the national prescription database covering all Danish pharmacies. We computed the breast cancer recurrence odds ratio (OR) and 95% confidence interval for each medication. The pooled recurrence OR was null (OR, 1.0; 95% confidence interval, 0.8-1.3); recurrence ORs for individual drugs ranged from 0.3 to 3.4. The individual ORs followed the pattern expected under a null-centered Gaussian distribution. Null associations were apparent for all drugs after empirical Bayes adjustment for multiple comparisons. Together, these results provide evidence for a null association between drug-compromised CYP2D6 activity and breast cancer recurrence among tamoxifen-treated women.
authors.affiliation: Department of Epidemiology, Boston University School of Public Health, 715 Albany Street, T3E, Boston, MA 02118, USA. tpa@bu.edu
authors.forename: Thomas P
authors.initials: TP
authors.lastname: Ahern
authors.forename: Lars
authors.initials: L
authors.lastname: Pedersen
authors.forename: Deirdre P
authors.initials: DP
authors.lastname: Cronin-Fenton
authors.forename: Henrik Toft
authors.initials: HT
authors.lastname: Sørensen
authors.forename: Timothy L
authors.initials: TL
authors.lastname: Lash
mesh_terms: D000328:Adult; D000368:Aged; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000201:enzymology / Q000473:pathology; D019389:Cytochrome P-450 CYP2D6 / Q000378:metabolism; D065690:Cytochrome P-450 CYP2D6 Inhibitors; D004791:Enzyme Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000201:enzymology / Q000473:pathology*; D012008:Recurrence; D013629:Tamoxifen / Q000008:administration & dosage / Q000627:therapeutic use*
chemical_list: D018931:Antineoplastic Agents, Hormonal; D065690:Cytochrome P-450 CYP2D6 Inhibitors; D004791:Enzyme Inhibitors; D013629:Tamoxifen; D019389:Cytochrome P-450 CYP2D6
references.citation: Eur J Clin Pharmacol. 2004 Jul;60(5):329-36
references.pmid: 15168101
references.citation: Acta Oncol. 2008;47(4):506-24
references.pmid: 18465317
references.citation: Br J Clin Pharmacol. 1992 Sep;34(3):262-5
references.pmid: 1389951
references.citation: Br J Cancer. 2008 Aug 19;99(4):616-21
references.pmid: 18665165
references.citation: Cancer Chemother Pharmacol. 2005 May;55(5):471-8
references.pmid: 15685451
references.citation: Lancet. 2005 May 14-20;365(9472):1687-717
references.pmid: 15894097
references.citation: Acta Oncol. 2008;47(4):497-505
references.pmid: 18465316
references.citation: Am J Public Health. 1989 Mar;79(3):340-9
references.pmid: 2916724
references.citation: Br J Clin Pharmacol. 2002 Aug;54(2):157-67
references.pmid: 12207635
references.citation: J Natl Cancer Inst. 2003 Dec 3;95(23):1758-64
references.pmid: 14652237
references.citation: Naunyn Schmiedebergs Arch Pharmacol. 2004 Jan;369(1):23-37
references.pmid: 14618296
references.citation: Lancet Oncol. 2009 Aug;10(8):825-33
references.pmid: 19647203
references.citation: Acta Obstet Gynecol Scand. 2004 May;83(5):476-81
references.pmid: 15059162
references.citation: Clin Pharmacol Ther. 2006 Jul;80(1):61-74
references.pmid: 16815318
references.citation: Eur J Clin Pharmacol. 1996;51(1):73-8
references.pmid: 8880055
references.citation: Epidemiology. 1991 Jul;2(4):244-51
references.pmid: 1912039
references.citation: Biochem Pharmacol. 1997 Jan 24;53(2):171-8
references.pmid: 9037249
references.citation: Cancer Epidemiol Biomarkers Prev. 2000 Sep;9(9):895-903
references.pmid: 11008906